Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life

References

• First biologic for allergy-related asthma. FDA Consum. 2003: 5.
   Google Scholar
• Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018;121(4):406–413. doi:10.1016/j.anai.2018.07.033
   PubMed Web of Science ®Google Scholar
• McCracken JL, Tripple JW, Calhoun WJ. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immunol. 2016;16(4):375–382. doi:10.1097/ACI.0000000000000284
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485. doi:10.1016/j.jaci.2015.09.008
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. doi:10.1002/14651858.CD003559.pub4
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Mplizou M, Porpodis K, et al. Long-term efficacy and safety of omalizumab in patients with allergic asthma: a real-life study. Allergy Asthma Proc. 2021;42(3):235–242. doi:10.2500/aap.2021.42.210014
   PubMed Web of Science ®Google Scholar
• Menzella F, Galeone C, Formisano D, et al. Real-life Efficacy of Omalizumab After 9 Years of Follow-up. Allergy Asthma Immunol Res. 2017;9(4):368–372. doi:10.4168/aair.2017.9.4.368
   PubMed Web of Science ®Google Scholar
• Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016;6(8):e011857. doi:10.1136/bmjopen-2016-011857
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–164.e1. doi:10.1016/j.jaip.2018.04.043
   PubMed Web of Science ®Google Scholar
• Bhutani M, Yang WH, Hébert J, de Takacsy F, Stril JL. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX observational study. PLoS One. 2017;12(8):e0183869. doi:10.1371/journal.pone.0183869
   PubMed Web of Science ®Google Scholar
• Al-Ahmad M, Arifhodzic N, Nurkic J, et al. “Real-life” efficacy and safety aspects of 4-year omalizumab treatment for asthma. Med Princ Pract. 2018;27(3):260–266. doi:10.1159/000487482
   PubMed Web of Science ®Google Scholar
• Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–412. doi:10.1016/j.jaci.2014.08.025
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed January 29, 2022.
   Google Scholar
• Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis. 2012;6(2):87–95. DOI:10.1177/1753465811429478
   PubMed Web of Science ®Google Scholar
• Schuler M, Faller H, Wittmann M, Schultz K. Asthma control test and asthma control questionnaire: factorial validity, reliability and correspondence in assessing status and change in asthma control. J Asthma. 2016;53(4):438–445. doi:10.3109/02770903.2015.1101134
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147(4):832–838. doi:10.1164/ajrccm/147.4.832
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Usmani OS, Bakakos P. Biologics in severe asthma: the overlap endotype - opportunities and challenges. Expert Opin Biol Ther. 2020;20(12):1427–1434. doi:10.1080/14712598.2020.1809651
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee FE, Lee GB, Phenotypes UA. Endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi:10.1007/s12016-018-8712-1
   PubMed Web of Science ®Google Scholar
• Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152–160. doi:10.1080/02770903.2017.1322611
   PubMed Web of Science ®Google Scholar
• Bousquet J, Humbert M, Gibson PG, et al. Real-World Effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021;9(7):2702–2714. doi:10.1016/j.jaip.2021.01.011
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610. doi:10.1111/all.12815
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi:10.1016/j.rmed.2013.04.017
   PubMed Web of Science ®Google Scholar
• Faulkner KM, MacDonald K, Abraham I, Alhossan A, Lee CS. ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Rev Clin Immunol. 2021;17(1):73–83. doi:10.1080/1744666X.2020.1856658
   PubMed Web of Science ®Google Scholar
• Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104(9):1381–1385. doi:10.1016/j.rmed.2010.06.001
   PubMed Web of Science ®Google Scholar
• Dalal AA, Duh MS, Gozalo L, et al. Dose-Response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22(7):833–847. doi:10.18553/jmcp.2016.22.7.833
   PubMedGoogle Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136(6):1488–1495. doi:10.1016/j.jaci.2015.07.046
   PubMed Web of Science ®Google Scholar
• Menzella F, Ghidoni G, Fontana M, et al. The role of systemic corticosteroids in severe asthma and new evidence in their management and tapering. Expert Rev Clin Immunol. 2021;17(12):1283–1299. doi:10.1080/1744666X.2021.20041
   PubMed Web of Science ®Google Scholar
• Holgate ST, Djukanović R, Casale T, Anti-immunoglobulin BJ. E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408–416. doi:10.1111/j.1365-2222.2005.02191.x
   PubMed Web of Science ®Google Scholar
• Harrison RG, MacRae M, Karsh J, Santucci S, Yang WH. Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience. Ann Allergy Asthma Immunol. 2015;115(1):77‐78. doi:10.1016/j.anai.2015.04.014
   PubMed Web of Science ®Google Scholar
• Kim HL, Leigh R, Omalizumab: BA. Practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol. 2010;6(1):32. doi:10.1186/1710-1492-6-32
   PubMedGoogle Scholar
• Iribarren C, Rahmaoui A, Long AA, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489–1495.e5. doi:10.1016/j.jaci.2016.07.038
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192. doi:10.1177/1753466618810192
   Web of Science ®Google Scholar